Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

BACKGROUND: There are few third-line or later (3L+) treatment options for advanced/metastatic (adv/met) gastric cancer/gastroesophageal junction cancers (GC/GEJC). 3L+ Nivolumab demonstrated encouraging results in Asian patients in the ATTRACTION-2 study compared with placebo (12-month survival, 26%...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gastric Cancer
Autors principals: Chau, Ian, Le, Dung T., Ott, Patrick A., Korytowsky, Beata, Le, Hannah, Le, T. Kim, Zhang, Ying, Sanchez, Teresa, Maglinte, Gregory A., Laurie, Melissa, Abraham, Pranav, Patel, Dhiren, Shangguan, Tong
Format: Artigo
Idioma:Inglês
Publicat: Springer Singapore 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942583/
https://ncbi.nlm.nih.gov/pubmed/31549264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-019-01008-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars